Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
Multistakeholder Approaches to Optimize Oncology Market Access Strategy
Effective oncology market access strategy has become markedly more complex as geopolitical pressures reshape how innovative cancer therapies reach patients, as made clear in Iroda Jurabekova’s pharma summit presentation. Determining whethe...
Advancing Real-World Evidence AI in Medicines Regulation
The adoption of Real-World Evidence AI is reshaping how the European Medicines Agency evaluates medicines, according to the European Medicines Agency’s annual report. By moving these technologies from pilot project...
Strengthening Medicine Shortages Management for Enhanced Availability and Access
The European Medicines Agency made medicine shortages management a foundational policy objective in 2025, as highlighted in its annual reports and work programmes. By advancing coordinated shortages oversight and d...